

=> d his


(FILE 'HOME' ENTERED AT 15:45:05 ON 27 MAR 2009)

FILE 'REGISTRY' ENTERED AT 15:45:17 ON 27 MAR 2009

L1 STRUCTURE UPLOADED
 L2 STRUCTURE UPLOADED
 L3 1 S L1 AND L2
 L4 16 S L1 AND L2 FULL


=> d que l4 stat

L1 STR



Structure attributes must be viewed using STN Express query preparation.

L2 STR



Structure attributes must be viewed using STN Express query preparation.


L4 16 SEA FILE=REGISTRY SSS FUL L1 AND L2

100.0% PROCESSED 17 ITERATIONS
 SEARCH TIME: 00.00.01

16 ANSWERS

=> d 12

L2 HAS NO ANSWERS
 L2 STR




Structure attributes must be viewed using STN Express query preparation.

=> d 1-16 ide can

L4 ANSWER 1 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 1089180-03-9 REGISTRY
ED Entered STN: 23 Dec 2008
CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2E)-2-butenedioate (1:?) (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H23 N5 O . x C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS

CM 1


CRN 145158-71-0
CMF C16 H23 N5 O



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 150:24285

REFERENCE 2: 150:24137

L4 ANSWER 2 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 1052274-43-7 REGISTRY
ED Entered STN: 24 Sep 2008
CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2E)-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

OTHER NAMES:


CN (E)-Tegaserod maleate
CN (E)-[(5-Methoxyindol-3-yl)methylenehydrazino](pentylamino)methaniminium maleate
FS STEREOSEARCH
MF C16 H23 N5 O . C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS, CHEMCATS

CM 1

CRN 1044642-88-7

CMF C16 H23 N5 O

Double bond geometry as shown.




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 149:343656

L4 ANSWER 3 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 944385-51-7 REGISTRY
ED Entered STN: 10 Aug 2007
CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate, hydrate (2:3:4) (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H23 N5 O . 3/2 C4 H4 O4 . 2 H2 O
SR CA
LC STN Files: CA, CAPLUS

CM 1


CRN 145158-71-0
CMF C16 H23 N5 O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 147:197350

L4 ANSWER 4 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 944385-50-6 REGISTRY
ED Entered STN: 10 Aug 2007
CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate (2:3) (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H23 N5 O . 3/2 C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS

CM 1


CRN 145158-71-0
CMF C16 H23 N5 O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 147:197350

L4 ANSWER 5 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 914100-15-5 REGISTRY
ED Entered STN: 28 Nov 2006
CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H23 N5 O . C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS

CM 1


CRN 145158-71-0
CMF C16 H23 N5 O



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 149:128733


REFERENCE 2: 149:128730

REFERENCE 3: 145:477955

L4 ANSWER 6 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 857305-37-4 REGISTRY
ED Entered STN: 27 Jul 2005
CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate (1:1), monohydrate (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H23 N5 O . C4 H4 O4 . H2 O
SR CA
LC STN Files: CA, CAPLUS

CM 1


CRN 145158-71-0
CMF C16 H23 N5 O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 143:115433

L4 ANSWER 7 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
 RN 855997-86-3 REGISTRY
 ED Entered STN: 19 Jul 2005
 CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate, compd. with 1,4-dioxane (2:1:2) (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C16 H23 N5 O . C4 H8 O2 . 1/2 C4 H4 O4
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 145158-71-0
 CMF C16 H23 N5 O



CM 2


CRN 123-91-1
 CMF C4 H8 O2



CM 3

CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.




1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 143:83499

L4 ANSWER 8 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 855997-84-1 REGISTRY
ED Entered STN: 19 Jul 2005
CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate, hydrate (2:1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate (2:1), monohydrate (9CI)
FS STEREOSEARCH
MF C16 H23 N5 O . 1/2 C4 H4 O4 . 1/2 H2 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1


CRN 145158-71-0
CMF C16 H23 N5 O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 147:474623


REFERENCE 2: 146:107665

REFERENCE 3: 143:83499

L4 ANSWER 9 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
 RN 855997-83-0 REGISTRY
 ED Entered STN: 19 Jul 2005
 CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate, compd. with ethanol (1:1:1) (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C16 H23 N5 O . C4 H4 O4 . C2 H6 O
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

CM 1


CRN 145158-71-0
 CMF C16 H23 N5 O



CM 2

CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.



CM 3

CRN 64-17-5
 CMF C2 H6 O

H₃C-CH₂-OH


1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 143:83499

L4 ANSWER 10 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
 RN 855997-82-9 REGISTRY
 ED Entered STN: 19 Jul 2005
 CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate, compd. with trichloromethane (1:1:1) (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C16 H23 N5 O . C4 H4 O4 . C H Cl3
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

CM 1


CRN 145158-71-0
 CMF C16 H23 N5 O



CM 2


CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.



CM 3

CRN 67-66-3
 CMF C H Cl3




1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 143:83499

L4 ANSWER 11 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
 RN 855997-81-8 REGISTRY
 ED Entered STN: 19 Jul 2005
 CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate, compd. with 1-propanol (1:1:1) (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C16 H23 N5 O . C4 H4 O4 . C3 H8 O
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

CM 1


CRN 145158-71-0
 CMF C16 H23 N5 O



CM 2

CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.



CM 3

CRN 71-23-8
 CMF C3 H8 O

H₃C-CH₂-CH₂-OH


1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 143:83499

L4 ANSWER 12 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
 RN 843609-66-5 REGISTRY
 ED Entered STN: 07 Mar 2005
 CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate, compd. with 2-propanol (1:1:?) (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C16 H23 N5 O . C4 H4 O4 . x C3 H8 O
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

CM 1


CRN 145158-71-0
 CMF C16 H23 N5 O



CM 2


CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.



CM 3

CRN 67-63-0
 CMF C3 H8 O




1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 142:225898

L4 ANSWER 13 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
 RN 843609-63-2 REGISTRY
 ED Entered STN: 07 Mar 2005
 CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate, compd. with ethanol (1:1:?) (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C16 H23 N5 O . C4 H4 O4 . x C2 H6 O
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

CM 1


CRN 145158-71-0
 CMF C16 H23 N5 O



CM 2

CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.



CM 3

CRN 64-17-5
 CMF C2 H6 O

H₃C-CH₂-OH


1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 142:225898

L4 ANSWER 14 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
 RN 843609-62-1 REGISTRY
 ED Entered STN: 07 Mar 2005
 CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate, compd. with 2-propanone (1:1:?) (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C16 H23 N5 O . C4 H4 O4 . x C3 H6 O
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

CM 1


CRN 145158-71-0
 CMF C16 H23 N5 O



CM 2


CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.



CM 3

CRN 67-64-1
 CMF C3 H6 O




1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 142:225898

L4 ANSWER 15 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
 RN 189188-57-6 REGISTRY
 ED Entered STN: 22 May 1997
 CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (Z)-2-butenedioate (1:1)
 OTHER NAMES:
 CN HTF 919
 CN SDZ-HTF 919
 CN Tegaserod hydrogen maleate
 CN Tegaserod maleate
 CN Zelmac
 CN Zelnorm
 FS STEREOSEARCH
 MF C16 H23 N5 O . C4 H4 O4
 SR CA
 LC STN Files: ADISINSIGHT, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CBNB, CHEMCATS, CSCHEM, DDFU, DRUGU, EMBASE, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, PHAR, PROUDDR, PS, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)

CM 1


CRN 145158-71-0
 CMF C16 H23 N5 O



CM 2

CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

113 REFERENCES IN FILE CA (1907 TO DATE)
 113 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 150:129377
 REFERENCE 2: 150:128688
 REFERENCE 3: 150:64070
 REFERENCE 4: 149:582435
 REFERENCE 5: 149:548963

REFERENCE 6: 149:394712

REFERENCE 7: 149:322960

REFERENCE 8: 149:274989


REFERENCE 9: 149:258435

REFERENCE 10: 149:252252

L4 ANSWER 16 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
 RN 145427-85-6 REGISTRY
 ED Entered STN: 21 Jan 1993
 CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (Z)-2-butenedioate (2:1) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (Z)-2-butenedioate (2:1)
 FS STEREOSEARCH
 MF C16 H23 N5 O . 1/2 C4 H4 O4
 SR CA
 LC STN Files: CA, CAPLUS, IMSPATENTS, IMSRESEARCH, TOXCENTER, USPATFULL

CM 1


CRN 145158-71-0
 CMF C16 H23 N5 O



CM 2

CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.



4 REFERENCES IN FILE CA (1907 TO DATE)
 4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 147:371820
 REFERENCE 2: 144:94399
 REFERENCE 3: 143:83499
 REFERENCE 4: 118:80801

```
=> fil capl
FILE 'CAPLUS' ENTERED AT 15:48:28 ON 27 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

```
FILE COVERS 1907 - 27 Mar 2009 VOL 150 ISS 14
FILE LAST UPDATED: 26 Mar 2009 (20090326/ED)
```

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

'FIONA' IS DEFAULT FORMAT FOR 'CAPLUS' FILE

```
=> s l4
L5      121 L4

=> s l4(L)(polymorph? or cryst)
      121 L4
      252532 POLYMORPH?
      384784 CRYST
      1802 CRYSTS
      386053 CRYST
          (CRYST OR CRYSTS)
L6      11 L4(L)(POLYMORPH? OR CRYST)

=> d 1-11 bib abs hitstr
```

L6 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2008:1487234 CAPLUS
 DN 150:24137
 TI Novel polymorphic forms of tegaserod fumarate and their use for treating gastrointestinal disorders
 IN Gaitonde, Abhay; Manojkumar, Bindu; Sonawane, Sandeep; Kokane, Dattatrey
 PA Generics UK Limited, UK; Mylan Development Centre Private Limited
 SO PCT Int. Appl., 26pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008149139	A2	20081211	WO 2008-GB50395	20080530
	W:				
	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI IN 2007-MU1040 A 20070604

AB The present invention relates to novel polymorphic forms of the fumarate salt of tegaserod, and to processes for the preparation of these novel polymorphic forms. The invention also relates to pharmaceutical compns. comprising these novel polymorphs, and to uses of said compns. for treating patients suffering from gastrointestinal disorders. Thus, tegaserod fumarate was added to 5 volume of methanol and heated to reflux (66°); the solution was cooled to 25° within 35 min and filtered; the solid product was dried at 35° under vacuum until a constant weight was obtained; the 1H NMR indicated formation of tegaserod fumarate; x-ray powder diffraction and DSC anal. data confirmed that the product obtained was a novel polymorph of tegaserod fumarate; chemical purity >99% (as measured by HPLC); polymorphic purity = high (as measured by DSC).

IT 1089180-03-9P

RL: PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (polymorphic forms of tegaserod fumarate and their use for treating gastrointestinal disorders)


RN 1089180-03-9 CAPLUS

CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2E)-2-butenedioate (1:?) (CA INDEX NAME)

CM 1

CRN 145158-71-0


CMF C16 H23 N5 O



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



L6 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2008:1484387 CAPLUS
 DN 150:24285
 TI Novel tegaserod salts and novel polymorphic forms of tegaserod succinate, tartrate, malonate, camphor sulfonate, mandelate, oxalate and fumarate, and their use for treating patients suffering from gastrointestinal disorders
 IN Gaitonde, Abhay; Manojkumar, Bindu; Sonawane, Sandeep; Kokane, Dattatrey
 PA Generics UK Ltd., UK; Mylan Development Centre Private Ltd.
 SO PCT Int. Appl., 35pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008149154	A2	20081211	WO 2008-GB50413	20080605
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI IN 2007-MU1065 A 20070605

AB The present invention relates to various novel salts of tegaserod and to novel polymorphic forms of various salts of tegaserod, including polymorphic forms of tegaserod succinate, tartrate, malonate, camphor sulfonate, mandelate, oxalate and fumarate. The invention further relates to processes for the preparation of these novel salts and novel polymorphic forms. The invention also relates to pharmaceutical compns. comprising these novel salts or novel polymorphs, and to uses of said compns. for treating patients suffering from gastrointestinal disorders. Thus, tegaserod free base was taken in 3.3 volume of methanol and added a solution of succinic acid (2 equiv) in 8 volume methanol; the reaction mixture was stirred at 25° for 30 min and filtered; the solid product was dried at 40° under vacuum until a constant weight was obtained; 1H NMR indicated formation of tegaserod succinate; x-ray powder diffraction and DSC anal. data confirmed that the product obtained was a novel polymorph of tegaserod succinate; chemical purity >99% (as measured by HPLC); polymorphic purity = high (as measured by DSC).

IT 1089180-03-9P

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (novel tegaserod salts and novel polymorphic forms of tegaserod succinate, tartrate, malonate, camphor sulfonate, mandelate, oxalate and fumarate, and their use for treating patients suffering from gastrointestinal disorders)


RN 1089180-03-9 CAPLUS

CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2E)-2-butenedioate (1:?) (CA INDEX NAME)

CM 1

CRN 145158-71-0

CMF C16 H23 N5 O




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




L6 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2008:972558 CAPLUS
 DN 149:252252
 TI Preparation of tegaserod maleate polymorphs
 IN Tacca, Alessandra; Malpezzi, Luciana
 PA Chemo Iberica, S.A., Spain
 SO Eur. Pat. Appl., 16pp.
 CODEN: EPXXDW

DT Patent
 LA English

FAN, CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1956002	A1	20080813	EP 2007-101855	20070207
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
PRAI	EP 2007-101855		20070207		
GI					



AB The present invention refers to two new tegaserod (I) maleate polymorphs (α and β) and to processes for their preparation I is treated with (S)-camphor-10-sulfonic acid to give the salt and then treated with maleic acid. Then I maleate was ground and heated at 65° under reduced pressure for 3 days to give form β .
 IT 189188-57-6P, Tegaserod maleate
 RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (tegaserod maleate polymorphs preparation)
 RN 189188-57-6 CAPLUS
 CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1


CRN 145158-71-0
 CMF C16 H23 N5 O



CM 2

CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.




RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2008:408751 CAPLUS
 DN 150:129377
 TI Crystalline forms and aqueous solubilities of an inflammatory bowel syndrome drug, tegaserod
 AU Srivijaya, R.; Vishweshwar, Peddy; Sreekanth, B. R.; Vyas, K.
 CS Department of Analytical Research, Discovery Research, Dr. Reddy's Laboratories Ltd., Hyderabad, 500 049, India
 SO CrystEngComm (2008), 10(3), 283-287
 CODEN: CRECF4; ISSN: 1466-8033
 URL: <http://www.rsc.org/Publishing/Journals/CE/article.asp?Journal=CE4&VolumeYear=200810&Volume=10&JournalCode=CE&MasterJournalCode=CE&SubYear=2008&type=Issue&Issue=3&x=11&y=5>
 PB Royal Society of Chemistry
 DT Journal; (online computer file)
 LA English
 AB Tegaserod is a 5-HT4 agonist used for the management of irritable bowel syndrome (IBS) and constipation. Two polymorphs (F and H) of Tegaserod free base (TFB), eight polymorphs (A, B, B1, B2, B3, C, D, and E) of Tegaserod maleate salt (TM), Tegaserod hemi-maleate and Tegaserod acetate forms have been patented. The present study describes novel forms of Tegaserod and crystal structures of TFB, its monohydrate (TFBH) and Tegaserod nicotinate salt methanol solvate (TNM). It was shown that TFB exists in a tautomeric form II, TFBH is more water-soluble than TFB, and TNM and unsolvated Tegaserod nicotinate (TN) salts are more water-soluble than the marketed maleate salt (form A).
 IT 189188-57-6, Tegaserod maleate
 RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (crystalline forms and aqueous solubilities of an inflammatory bowel syndrome drug, tegaserod)
 RN 189188-57-6 CAPLUS
 CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1


CRN 145158-71-0
 CMF C16 H23 N5 O



CM 2

CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2007:1300723 CAPLUS
 DN 147:539679
 TI Alleles and polymorphisms associated with type 2 diabetes mellitus and obesity and their diagnostic use
 IN Salonen, Jukka T.; Hyppönen, Jelenä; Kaikkonen, Jari; Pirskanen, Mia; Uimari, Pekka; Aalto, Juha-Matti
 PA Oy Jurilab Ltd., Finland
 SO PCT Int. Appl., 456pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007128884	A1	20071115	WO 2007-FI50266	20070509
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	US 20070292412	A1	20071220	US 2007-798002	20070509
	EP 2021502	A1	20090211	EP 2007-730753	20070509
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
PRAI	US 2006-798706P	P	20060509		
	US 2006-798774P	P	20060509		
	US 2006-805522P	P	20060622		
	US 2006-819015P	P	20060707		
	US 2006-827306P	P	20060928		
	US 2006-863438P	P	20061030		
	US 2006-864681P	P	20061107		
	WO 2007-FI50266	W	20070509		

AB Genes, SNP markers and haplotypes that are markers of susceptibility or predisposition to type 2 diabetes and obesity and related medical conditions are disclosed. Methods for diagnosis, prediction of clin. course and efficacy of treatments for type 2 diabetes, obesity and related phenotypes using polymorphisms in the risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of type 2 diabetes and related traits. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of type 2 diabetes. Novel methods for prevention and 10 treatment of metabolic diseases such as type 2 diabetes based on the disclosed type 2 diabetes genes, polypeptides and related pathways are also disclosed.

IT 189188-57-6
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (target for, in treatment of diabetes; alleles and polymorphisms associated with type 2 diabetes and obesity and their diagnostic use)


RN 189188-57-6 CAPLUS

CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 145158-71-0

CMF C16 H23 N5 O




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2007:814348 CAPLUS
 DN 147:197350
 TI Maleate salt of tegaserod and crystalline forms thereof
 IN Frenkel, Gustavo; Ini, Santiago; Koltai, Tamas
 PA Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc.
 SO PCT Int. Appl., 17pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN. CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007084761	A1	20070726	WO 2007-US1644	20070118
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 20070208072	A1	20070906	US 2007-655510	20070118
	US 20070225507	A1	20070927	US 2007-655511	20070118
PRAI	US 2006-760306P	P	20060118		
	US 2006-872950P	P	20061204		

AB Provided is sesqui-tegaserod maleate and processes for preparation thereof. To a mixture of N-amino-N'-pentylguanidine hydriodide in water was added 5-methoxy-1H-indole-3-carboxaldehyde followed by NaOH and stirred at room temperature. The resulting solution was treated with a solution of maleic acid to give tegaserod maleate.

IT 189188-57-6P, Tegaserod maleate 944385-50-6P
 944385-51-7P

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (maleate salt of tegaserod and crystalline forms thereof)


RN 189188-57-6 CAPLUS

CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 145158-71-0

CMF C16 H23 N5 O




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



RN 944385-50-6 CAPLUS
 CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate (2:3) (CA INDEX NAME)

CM 1


CRN 145158-71-0
 CMF C16 H23 N5 O



CM 2

CRN 110-16-7
 CMF C4 H4 O4


Double bond geometry as shown.



RN 944385-51-7 CAPLUS
 CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate, hydrate (2:3:4) (CA INDEX NAME)

CM 1


CRN 145158-71-0
 CMF C16 H23 N5 O



CM 2

CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.




RE. CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2007:814347 CAPLUS
 DN 147:197349
 TI Process for preparing a crystalline form of tegaserod maleate
 IN Frenkel, Gustavo; Ini, Santiago
 PA Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc.
 SO PCT Int. Appl., 11pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN. CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007084697	A2	20070726	WO 2007-US1492	20070118
	WO 2007084697	A3	20070913		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	US 20070208072	A1	20070906	US 2007-655510	20070118
	US 20070225507	A1	20070927	US 2007-655511	20070118
PRAI	US 2006-760306P	P	20060118		
	US 2006-872950P	P	20061204		
AB	Provided is a process for preparing tegaserod maleate. To a mixture of 5-methoxy-1H-indole-3-carboxaldehyde and NaOH was added a solution of N-amino-N'-pentylguanidine hydroiodide in water. The product obtained was treated with maleic acid to give tegaserod maleate.				
IT	189188-57-6P, Tegaserod maleate RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (process for preparing crystalline form of tegaserod maleate)				
RN	189188-57-6 CAPLUS				
CN	Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)				

CM 1


CRN 145158-71-0
 CMF C16 H23 N5 O



CM 2

CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.



L6 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2007:13694 CAPLUS

DN 146:107665

TI Polymorphic forms of tegaserod maleate

IN Ini, Santiago; Koltai, Tamas; Pinchasov, Michael; Gorohovsky, Sofia;
Frenkel, Gustavo

PA Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA,
Inc.

SO PCT Int. Appl., 40pp.

CODEN: PIXXD2

DT Patent

LA English


FAN, CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007002314	A2	20070104	WO 2006-US24348	20060622
	WO 2007002314	A3	20070628		
	WO 2007002314	A9	20070823		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	US 20070112057	A1	20070517	US 2006-473582	20060622
	BR 2006005901	A	20071218	BR 2006-5901	20060622
	EP 1893195	A2	20080305	EP 2006-785363	20060622
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
	JP 2008514734	T	20080508	JP 2007-534928	20060622
	KR 2007062504	A	20070615	KR 2007-703873	20070216
	MX 2007002113	A	20070427	MX 2007-2113	20070220
	JP 2007297377	A	20071115	JP 2007-84885	20070328
	MX 2007016179	A	20080311	MX 2007-16179	20071214
PRAI	US 2005-693301P	P	20050622		
	US 2005-704048P	P	20050728		
	US 2005-721729P	P	20050928		
	US 2005-729258P	P	20051020		
	US 2006-773066P	P	20060213		
	US 2006-792811P	P	20060417		
	US 2006-792801P	P	20060417		
	US 2006-796739P	P	20060501		
	JP 2007-534928	A3	20060622		
	WO 2006-US24348	W	20060622		
	US 2006-872955P	P	20061204		
	US 2007-899166P	P	20070201		
	US 2007-902418P	P	20070220		
	US 2007-903988P	P	20070227		
AB	Provided are crystalline forms of tegaserod maleate and processes for the preparation thereof. Tegaserod maleate was dissolved in water and ethanol absolute at reflux temperature. After removal of the solvents, the product was analyzed by XRD and found to be mixture of Forms B3 and A.				
IT	189188-57-6, Tegaserod maleate RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (polymorphic forms of tegaserod maleate)				
RN	189188-57-6 CAPLUS				
CN	Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)				

CM 1

CRN 145158-71-0

CMF C16 H23 N5 O




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



IT 855997-84-1

RL: RCT (Reactant); RACT (Reactant or reagent)
(polymorphic forms of tegaserod maleate)


RN 855997-84-1 CAPLUS

CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate, hydrate (2:1:1) (CA INDEX NAME)

CM 1

CRN 145158-71-0

CMF C16 H23 N5 O




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



L6 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2006:1347213 CAPLUS
 DN 146:369280
 TI Study on crystal forms of tegaserod maleate
 AU Li, Zhonghong; Wang, Yu; Yang, Yu; Ni, Kunyi
 CS Jiangsu Institute for Drug Control, Nanjing, Jiangsu Province, 210008, Peop. Rep. China
 SO Yaowu Fenxi Zazhi (2005), 25(11), 1346-1349
 CODEN: YFZADL; ISSN: 0254-1793
 PB Yaowu Fenxi Zazhi Bianji Weiyuanhui
 DT Journal
 LA English
 AB To investigate the phys. characters of the 2 crystal forms of tegaserod maleate, FTIR, Raman spectroscopy, thermal anal. and powder x-ray diffraction were applied to study the crystal forms of tegaserod maleate. Crystallized from different solvents, tegaserod maleate had 2 crystal forms. Both of the crystal forms of tegaserod maleate had same m.ps., and their DSC and TG curves were same, too. But their IR spectra, Raman spectroscopy, and powder x-ray diffraction patterns were different. FTIR, Raman spectroscopy, and powder x-ray diffraction were the effective methods to characterize the 2 crystal forms of tegaserod maleate.
 IT 189188-57-6, Tegaserod maleate
 RL: PRP (Properties)
 (polymorphism of tegaserod maleate studied via FTIR, Raman spectroscopy, thermal anal., and powder x-ray diffractometry)
 RN 189188-57-6 CAPLUS
 CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1


CRN 145158-71-0
 CMF C16 H23 N5 O



CM 2

CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2005:567159 CAPLUS
 DN 143:83499
 TI Polymorphic forms of tegaserod base and salts
 IN Mendelovici, Marioara; Aronhime, Judith; Ini, Santiago; Sterimbaum, Greta;
 Luvchick, Eran
 PA Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA,
 Inc.
 SO PCT Int. Appl., 65 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN, CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005058819	A2	20050630	WO 2004-US42822	20041216
	WO 2005058819	A3	20050804		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2550886	A1	20050630	CA 2004-2550886	20041216
	US 20050165085	A1	20050728	US 2004-15875	20041216
	EP 1594493	A2	20051116	EP 2004-814954	20041216
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU			
	JP 2007514000	T	20070531	JP 2006-545559	20041216
	IN 2006DN03627	A	20070824	IN 2006-DN3627	20060623
	KR 2006111675	A	20061027	KR 2006-713882	20060710
PRAI	US 2003-530278P	P	20031216		
	US 2004-585423P	P	20040702		
	US 2004-609715P	P	20040914		
	WO 2004-US42822	W	20041216		

AB Polymorphic forms of tegaserod base and its maleate salt, and processes for their preparation are disclosed. Tegaserod maleate was combined with MeCn and heated to reflux until dissoln. of the drug to give the form A of the drug.

IT 145427-85-6P 189188-57-6P, Tegaserod maleate
 855997-84-1P 855997-86-3P
 RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (polymorphic forms of tegaserod base and salts)


RN 145427-85-6 CAPLUS

CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate (2:1) (CA INDEX NAME)

CM 1

CRN 145158-71-0

CMF C16 H23 N5 O




CM 2

CRN 110-16-7

CMF C4 H4 04

Double bond geometry as shown.




RN 189188-57-6 CAPLUS

CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 145158-71-0

CMF C16 H23 N5 0




CM 2

CRN 110-16-7

CMF C4 H4 04

Double bond geometry as shown.




RN 855997-84-1 CAPLUS

CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate, hydrate (2:1:1) (CA INDEX NAME)

CM 1

CRN 145158-71-0


CMF C16 H23 N5 0



CM 2

CRN 110-16-7
CMF C4 H4 O4


Double bond geometry as shown.



RN 855997-86-3 CAPLUS
CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate, compd. with 1,4-dioxane (2:1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 145158-71-0
CMF C16 H23 N5 O



CM 2


CRN 123-91-1
CMF C4 H8 O2



CM 3

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




IT 855997-81-8 855997-82-9 855997-83-0
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(polymorphic forms of tegaserod base and salts)

RN 855997-81-8 CAPLUS
CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate, compd. with 1-propanol (1:1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 145158-71-0
CMF C16 H23 N5 O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



CM 3


CRN 71-23-8
CMF C3 H8 O

H₃C-CH₂-CH₂-OH

RN 855997-82-9 CAPLUS
CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate, compd. with trichloromethane (1:1:1) (9CI) (CA
INDEX NAME)

CM 1


CRN 145158-71-0
CMF C16 H23 N5 O



CM 2

CRN 110-16-7
CMF C4 H4 O4


Double bond geometry as shown.



CM 3

CRN 67-66-3

CMF C H Cl3




RN 855997-83-0 CAPLUS

CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate, compd. with ethanol (1:1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 145158-71-0

CMF C16 H23 N5 O




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



CM 3

CRN 64-17-5

CMF C2 H6 O



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2004:817858 CAPLUS
 DN 141:320073
 TI Novel crystalline forms of tegaserod maleate
 IN Parthasaradhi, Reddy Bandi; Rathnakar, Reddy Kura; Raji, Reddy Rapolu;
 Muralidhara, Reddy Dasari; Srinivas, Reddy Itiyala
 PA Hetero Drugs Limited, India
 SO PCT Int. Appl., 15 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004085393	A1	20041007	WO 2003-IN76	20030325
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003222439	A1	20041018	AU 2003-222439	20030325
	IN 2003CN00777	A	20050415	IN 2003-CN777	20030521
	US 20050119328	A1	20050602	US 2004-508905	20040923
PRAI	WO 2003-IN76	A	20030325		

AB The present invention relates to novel crystalline forms of tegaserod maleate, to processes for their preparation and to pharmaceutical compns. containing them. (A) tegaserod maleate Form I is prepared by (i) adding maleic acid to a solution of tegaserod free base in acetone, and (ii) isolating tegaserod maleate Form I, (B) tegaserod maleate Form II is prepared by (i) dissolving tegaserod maleate in methanol, and (ii) precipitating tegaserod maleate Form II from the solution by mixing with acetonitrile, (C) tegaserod maleate Form III is prepared by (i) mixing maleic acid and a solution of tegaserod free base in methanol, and (ii) collecting the tegaserod maleate Form III solid separated by filtration, and (D) tegaserod maleate Form IV is prepared by (i) mixing maleic acid and a solution of tegaserod free base in methanol, and (ii) precipitating tegaserod maleate Form IV by mixing with methylene dichloride or iso-Pr alc. For example, to a solution of 10 g of tegaserod free base, dissolved in 100 mL of acetone (100 mL), was added 4 g of maleic acid and the contents were maintained for 1 h at 25°. The separated solid is filtered to give 12.5 g of tegaserod maleate Form I.

IT 189188-57-6P, Tegaserod maleate
 RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (preparation of crystalline forms of tegaserod maleate for dosage forms)


RN 189188-57-6 CAPLUS

CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 145158-71-0

CMF C16 H23 N5 O




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> s l4 and modification?)  
UNMATCHED RIGHT PARENTHESIS ' IFICATION?)'
```

```
=> s l4 and modification?  
      121 L4  
      445819 MODIFICATION?  
L7      2 L4 AND MODIFICATION?
```

```
=> d 1-2 bib abs hitstr
```

L7 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2007:618179 CAPLUS
 DN 147:39163
 TI Composition comprising 5-HT4 agonist for treatment of irritable bowel syndrome
 IN Levy, Stephane David
 PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SO PCT Int. Appl., 9pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007062837	A2	20070607	WO 2006-EP11488	20061130
	WO 2007062837	A3	20070719		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRAI GB 2005-24668 A 20051202

AB The invention relates to a pharmaceutical composition, use, or method in the treatment of irritable bowel syndrome (IBS) characterized by mixed or alternating bowel habits based on a modification of the Rome II criteria (IBS-M), with 5-hydroxytryptamine type-4 receptor agonists (5-HT4 agonists), in particular tegaserod.

IT 189188-57-6, Tegaserod maleate
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (composition comprising 5-HT4 agonist for treatment of irritable bowel syndrome)


RN 189188-57-6 CAPLUS

CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 145158-71-0

CMF C16 H23 N5 O




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2005:141030 CAPLUS
 DN 142:225898
 TI Stable modifications of tegaserod hydrogen maleate
 IN Pfeffer, Sabine; Vitzling, Christian
 PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SO PCT Int. Appl., 31 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005014544	A1	20050217	WO 2004-EP8281	20040723
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004263285	A1	20050217	AU 2004-263285	20040723
	CA 2532351	A1	20050217	CA 2004-2532351	20040723
	EP 1651601	A1	20060503	EP 2004-763452	20040723
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1826318	A	20060830	CN 2004-80021354	20040723
	BR 2004012830	A	20060926	BR 2004-12830	20040723
	JP 2006528609	T	20061221	JP 2006-520806	20040723
	EP 1880992	A1	20080123	EP 2007-117155	20040723
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	SG 144944	A1	20080828	SG 2008-5476	20040723
	RU 2349585	C2	20090320	RU 2006-105481	20040723
	US 20070112056	A1	20070517	US 2006-565454	20060120
	KR 2006040710	A	20060510	KR 2006-701500	20060123
	IN 2006CN00281	A	20070706	IN 2006-CN281	20060123
	MX 2006000917	A	20060330	MX 2006-917	20060124
	NO 2006000915	A	20060424	NO 2006-915	20060224
	AU 2007254641	A1	20080124	AU 2007-254641	20071221
PRAI	US 2003-489638P	P	20030724		
	AU 2004-263285	A3	20040723		
	EP 2004-763452	A3	20040723		
	WO 2004-EP8281	W	20040723		
GI					



AB The present invention relates to crystalline forms of tegaserod (I) hydrogen maleate, their use, in pharmaceutical compns. useful in the treatment of irritable bowel syndrome, gastro-esophageal reflux disease, functional dyspepsia, chronic constipation or diarrhea, and their production I was prepared, converted to the H maleate and crystal modifications A,

B, acetone and ethanol solvate prepared Tablets were prepared containing modification A.

IT 189188-57-6P, Tegaserod maleate 843609-62-1P, Tegaserod maleate acetone solvate 843609-63-2P, Tegaserod maleate ethanol solvate 843609-66-5P, Tegaserod maleate isopropanol solvate
 RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (stable modifications of tegaserod hydrogen maleate)


RN 189188-57-6 CAPLUS

CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 145158-71-0

CMF C16 H23 N5 O




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 843609-62-1 CAPLUS

CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate, compd. with 2-propanone (1:1:?) (9CI) (CA INDEX NAME)

CM 1

CRN 145158-71-0

CMF C16 H23 N5 O




CM 2


CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




CM 3

CRN 67-64-1
CMF C3 H6 0

RN 843609-63-2 CAPLUS
CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate, compd. with ethanol (1:1:?) (9CI) (CA INDEX NAME)


CM 1

CRN 145158-71-0
CMF C16 H23 N5 0


CM 2

CRN 110-16-7
CMF C4 H4 04

Double bond geometry as shown.




CM 3

CRN 64-17-5
CMF C2 H6 0

RN 843609-66-5 CAPLUS
CN Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2Z)-2-butenedioate, compd. with 2-propanol (1:1:?) (9CI) (CA INDEX NAME)

CM 1


CRN 145158-71-0
 CMF C16 H23 N5 O



CM 2


CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.



CM 3

CRN 67-63-0
 CMF C3 H8 O



RE. CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => d que l11 stat

L8	13	SEA	FILE=CAPLUS	ABB=ON	PLU=ON	"PFEFFER SABINE"/AU
L9	5	SEA	FILE=CAPLUS	ABB=ON	PLU=ON	("VITZLING C"/AU OR "VITZLING CHRISTIAN"/AU)
L10	17	SEA	FILE=CAPLUS	ABB=ON	PLU=ON	L8 OR L9
L11	4	SEA	FILE=CAPLUS	ABB=ON	PLU=ON	L10 AND TEGASEROD


=> d 1-4 bib abs

L11 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2005:141030 CAPLUS
 DN 142:225898
 TI Stable modifications of tegaserod hydrogen maleate
 IN Pfeffer, Sabine; Vitzling, Christian
 PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SO PCT Int. Appl., 31 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005014544	A1	20050217	WO 2004-EP8281	20040723
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004263285	A1	20050217	AU 2004-263285	20040723
	CA 2532351	A1	20050217	CA 2004-2532351	20040723
	EP 1651601	A1	20060503	EP 2004-763452	20040723
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1826318	A	20060830	CN 2004-80021354	20040723
	BR 2004012830	A	20060926	BR 2004-12830	20040723
	JP 2006528609	T	20061221	JP 2006-520806	20040723
	EP 1880992	A1	20080123	EP 2007-117155	20040723
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	SG 144944	A1	20080828	SG 2008-5476	20040723
	RU 2349585	C2	20090320	RU 2006-105481	20040723
	US 20070112056	A1	20070517	US 2006-565454	20060120
	KR 2006040710	A	20060510	KR 2006-701500	20060123
	IN 2006CN00281	A	20070706	IN 2006-CN281	20060123
	MX 2006000917	A	20060330	MX 2006-917	20060124
	NO 2006000915	A	20060424	NO 2006-915	20060224
	AU 2007254641	A1	20080124	AU 2007-254641	20071221
PRAI	US 2003-489638P	P	20030724		
	AU 2004-263285	A3	20040723		
	EP 2004-763452	A3	20040723		
	WO 2004-EP8281	W	20040723		
GI					



AB The present invention relates to crystalline forms of tegaserod (I) hydrogen maleate, their use, in pharmaceutical compns. useful in the treatment of irritable bowel syndrome, gastro-esophageal reflux disease, functional dyspepsia, chronic constipation or diarrhea, and their production I was prepared, converted to the H maleate and crystal modifications A, B,

acetone and ethanol solvate prepared Tablets were prepared containing
modification A.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2004:857381 CAPLUS
 DN 141:337762
 TI Oral suspension of tegaserod
 IN Bizot, Marie-Noelle; Iwicki, Mark Thomas; Vitzling, Christian
 PA Novartis Ag, Switz.; Novartis Pharma GmbH
 SO PCT Int. Appl., 14 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004087135	A1	20041014	WO 2004-EP3368	20040330
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004226797	A1	20041014	AU 2004-226797	20040330
	CA 2518533	A1	20041014	CA 2004-2518533	20040330
	EP 1610777	A1	20060104	EP 2004-724263	20040330
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004008914	A	20060328	BR 2004-8914	20040330
	CN 1764452	A	20060426	CN 2004-80008088	20040330
	CN 100352436	C	20071205		
	JP 2006522049	T	20060928	JP 2006-504921	20040330
	IN 2005CN02451	A	20070406	IN 2005-CN2451	20050929
	HK 1087619	A1	20080725	HK 2006-107829	20060713
	US 20070043102	A1	20070222	US 2006-551218	20060724
PRAI	GB 2003-7440	A	20030331		
	WO 2004-EP3368	A	20040330		

AB This invention relates to an oral suspension of tegaserod or pharmaceutically acceptable salts thereof. In particular, it relates to an oral suspension comprising an effective amount of tegaserod or a pharmaceutically acceptable salt thereof in a beverage, e.g. apple juice.

RE. CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2003:488556 CAPLUS
 DN 139:41862
 TI Solid pharmaceutical composition for oral administrations of
 tegaserod
 IN Vitzling, Christian; Aubert, Jerome
 PA Novartis AG, Switz.
 SO Eur. Pat. Appl., 9 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1321142	A1	20030625	EP 2001-403339	20011221
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	EG 24194	A	20081014	EG 2002-1358	20021217
	TW 260221	B	20060821	TW 2002-91136675	20021219
	CA 2470668	A1	20030703	CA 2002-2470668	20021220
	WO 2003053432	A1	20030703	WO 2002-EP14674	20021220
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
	RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR				
	AU 2002361198	A1	20030709	AU 2002-361198	20021220
	AU 2002361198	B2	20060608		
	EP 1458377	A1	20040922	EP 2002-796711	20021220
	EP 1458377	B1	20060322		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002015148	A	20041019	BR 2002-15148	20021220
	IN 2002MA00970	A	20050304	IN 2002-MA970	20021220
	CN 1606438	A	20050413	CN 2002-825532	20021220
	JP 2005516946	T	20050609	JP 2003-554189	20021220
	HU 2004002492	A2	20050728	HU 2004-2492	20021220
	HU 2004002492	A3	20080428		
	AT 320807	T	20060415	AT 2002-796711	20021220
	NZ 533585	A	20060428	NZ 2002-533585	20021220
	PT 1458377	T	20060731	PT 2002-796711	20021220
	ES 2258171	T3	20060816	ES 2002-796711	20021220
	RU 2322978	C2	20080427	RU 2004-122631	20021220
	IL 162451	A	20090211	IL 2002-162451	20021220
	MX 2004006157	A	20041027	MX 2004-6157	20040621
	NO 2004002779	A	20040917	NO 2004-2779	20040701
	US 20050106236	A1	20050519	US 2004-499721	20041221
	ZA 2004004467	A	20060531	ZA 2004-4467	20060328
PRAI	EP 2001-403339	A	20011221		
	WO 2002-EP14674	W	20021220		

AB A solid pharmaceutical composition for oral administration comprises tegaserod in a base or salt form (up to 10% by weight), a bulking agent at 70-90% by weight, a disintegrant at <14% a glidant and a lubricant. Thus, tablets contained tegaserod maleate 6.65, spray-dried lactose 76.85, Crospovidone 10.00, Aerosil 0.50, and Compritol ATO-800 <0.3%.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2000:144701 CAPLUS
 DN 132:185442
 TI New oral formulation for 5-HT4 agonists or antagonists
 IN De Bruijn, Karel; Engel, Gunter; Pfannkuche, Hans-Jurgen; Thewissen, Michael; Vitzling, Christian; Zuger, Othmar
 PA Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m. b. H.
 SO PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000010526	A2	20000302	WO 1999-EP6083	19990819
	WO 2000010526	A3	20000908		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	TW 238725	B	20050901	TW 1999-88114109	19990818
	CA 2338794	A1	20000302	CA 1999-2338794	19990819
	CA 2338794	C	20090120		
	AU 9956232	A	20000314	AU 1999-56232	19990819
	AU 762829	B2	20030703		
	IT 99MI1826	A1	20010219	IT 1999-MI1826	19990819
	BR 9913135	A	20010508	BR 1999-13135	19990819
	EP 1104289	A2	20010606	EP 1999-942892	19990819
	EP 1104289	B1	20060201		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
	TR 200100361	T2	20010621	TR 2001-361	19990819
	HU 2001003431	A2	20020128	HU 2001-3431	19990819
	HU 2001003431	A3	20020228		
	EE 200100104	A	20020617	EE 2001-104	19990819
	EE 5054	B1	20080815		
	TR 200102259	T2	20020621	TR 2001-2259	19990819
	JP 2002523351	T	20020730	JP 2000-565848	19990819
	JP 4048024	B2	20080213		
	NZ 509832	A	20031128	NZ 1999-509832	19990819
	CN 1165293	C	20040908	CN 1999-809924	19990819
	CN 1589906	A	20050309	CN 2004-10063873	19990819
	RU 2260424	C2	20050920	RU 2001-106999	19990819
	AT 316782	T	20060215	AT 1999-942892	19990819
	ES 2257869	T3	20060801	ES 1999-942892	19990819
	SK 285255	B6	20060907	SK 2001-243	19990819
	TR 200400187	T2	20061121	TR 2004-187	19990819
	PL 194069	B1	20070430	PL 1999-346764	19990819
	IL 141236	A	20080210	IL 1999-141236	19990819
	FR 2782454	A1	20000225	FR 1999-10666	19990820
	FR 2782454	B1	20051202		
	FR 2784899	A1	20000428	FR 1999-14897	19991126
	FR 2784899	B1	20010817		
	FR 2799123	A1	20010406	FR 2000-10748	20000821
	FR 2799123	B1	20051202		
	ZA 2001001095	A	20020508	ZA 2001-1095	20010208
	BG 105257	A	20011130	BG 2001-105257	20010214
	BG 65322	B1	20080229		
	IN 2001CN00226	A	20050304	IN 2001-CN226	20010216
	NO 2001000863	A	20010326	NO 2001-863	20010220
	MX 2001001854	A	20010629	MX 2001-1854	20010220

HR 2001000123	A1	20020228	HR 2001-123	20010220
HK 1038179	A1	20060908	HK 2001-107619	20011031
IN 2003CN00812	A	20050422	IN 2003-CN812	20030523
US 20030236183	A1	20031225	US 2003-620178	20030715
AU 2003248212	A1	20031030	AU 2003-248212	20030922
AU 2006200048	A1	20060202	AU 2006-200048	20060106
US 20080075773	A1	20080327	US 2007-947769	20071129
PRAI GB 1998-18340	A	19980821		
GB 1998-23477	A	19981027		
GB 1999-10320	A	19990505		
GB 1999-11059	A	19990512		
WO 1999-EP6083	W	19990819		
US 2000-501364	A3	20000210		
IN 2001-CN226	A3	20010216		
AU 2003-248212	A3	20030922		
AB	A pharmaceutical composition, in particular a composition for administering active agents which are poorly soluble in aqueous media, and/or which are acid sensitive is disclosed. A tablet contained tegaserod hydrogen maleate 8.31, Polyplasdone XL 50.00, glyceryl monostearate 12.50, Poloxalkol 2.50, lactose 200 mesh 37.94, HPMC 6.25, polyethylene glycol-4000 7.50, and water 3.00 mg.			
RE.CNT 9	THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT			

=> d his full

(FILE 'HOME' ENTERED AT 15:45:05 ON 27 MAR 2009)

FILE 'REGISTRY' ENTERED AT 15:45:17 ON 27 MAR 2009

L1 STRUCTURE UPLOADED
 D
L2 STRUCTURE UPLOADED
L3 1 SEA SSS SAM L1 AND L2
 D SCAN
L4 16 SEA SSS FUL L1 AND L2
 D QUE L4 STAT
 D L2
 D 1-16 IDE CAN

FILE 'CAPLUS' ENTERED AT 15:48:28 ON 27 MAR 2009
L5 121 SEA ABB=ON PLU=ON L4
L6 11 SEA ABB=ON PLU=ON L4(L) (POLYMORPH? OR CRYST)
 D 1-11 BIB ABS HITSTR
L7 2 SEA ABB=ON PLU=ON L4 AND MODIFICATION?
 D 1-2 BIB ABS HITSTR
 E PFEFFER SABINE/AU
L8 13 SEA ABB=ON PLU=ON "PFEFFER SABINE"/AU
 E VITZLING CHRISTIAN/AU
L9 5 SEA ABB=ON PLU=ON ("VITZLING C"/AU OR "VITZLING CHRISTIAN"/AU
)
L10 17 SEA ABB=ON PLU=ON L8 OR L9
L11 4 SEA ABB=ON PLU=ON L10 AND TEGASEROD
 D QUE L11 STAT
 D 1-4 BIB ABS

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 MAR 2009 HIGHEST RN 1127762-87-1

DICTIONARY FILE UPDATES: 26 MAR 2009 HIGHEST RN 1127762-87-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

FILE CAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Mar 2009 VOL 150 ISS 14
FILE LAST UPDATED: 26 Mar 2009 (20090326/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
107.00	332.30

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-13.94	-13.94

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 15:55:35 ON 27 MAR 2009